Clinical Trial Update: Efficacy Study of IgY (Antibody Against Pseudomonas) in Cystic Fibrosis Patients [Phase 3]

View source ↗

Summary

A Phase 3 efficacy study evaluating IgY antibody against Pseudomonas in cystic fibrosis patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• IgY (Antibody Against Pseudomonas) (IgY anti-Pseudomonas antibody)

Snippet

Sponsor: Mukoviszidose Institut gGmbH | Conditions: Cystic Fibrosis | Phase 3 | Status: COMPLETED